FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder February 25, 2025 February 25, 2025
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia February 10, 2025 February 10, 2025
The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement February 6, 2025 February 6, 2025
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization January 29, 2025 January 29, 2025
